Loading
companiesCompany
Ascentage Pharma
Ascentage is a Chinese biotechnology company built on protein-protein interaction inhibitors: olverembatinib, a third-generation BCR-ABL inhibitor approved in China for T315I-mutant chronic myeloid leukaemia, and the BCL-2 inhibitor lisaftoclax.
Also called: Ascentage Pharma Group Inc.亚盛医药
Overview
Ascentage Pharma, based in Suzhou and listed in Hong Kong and, since 2025, on Nasdaq, designs small molecules that block protein-protein interactions in apoptosis and other pathways. Olverembatinib (HQP1351), a BCR-ABL inhibitor active against the T315I mutation, was approved in China in 2021 for resistant chronic myeloid leukaemia and is in global trials with Takeda. Lisaftoclax (APG-2575) is a BCL-2 inhibitor in phase 3 trials in chronic lymphocytic leukaemia and other blood cancers. OnCo records it as a registry sponsor of phase 3 cancer trials.
Headquarters
Suzhou, CN
Scorecard
All companies#239of 1244 companies, score 21
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +10
1 approved, 0 in phase 3, 0 earlier, 1 targets, 24 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedOral third-generation BCR-ABL tyrosine kinase inhibitor
Olverembatinib is Ascentage Pharma's third-generation BCR-ABL inhibitor, approved in China in 2021 for chronic myeloid leukaemia carrying the T315I mutation, and now in global phase 3 trials against the established drugs; it was the one China-only approval OnCo found missing from the headline list.
Similar pages
- TreatmentOmacetaxine mepesuccinate
Shares Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML, BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML).
- TargetLYN kinase
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
- CancerT-cell prolymphocytic leukaemia
Shares A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL, Chronic lymphocytic leukaemia.
- CancerChronic myeloid leukaemia, chronic phase
Shares Study of Olverembatinib (HQP1351) in Patients With CML-CP, Olverembatinib, BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML).
- TrialA First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Chronic myeloid leukaemia (CML), Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
- PersonJanet Rowley
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Acute myeloid leukaemia.
- JournalLeukemia research
Shares Chronic myeloid leukaemia (CML), Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
- PersonAnthony Letai
Shares BCL-2, Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
cancers
fronts
targets
drugs
ApprovedOral third-generation BCR-ABL tyrosine kinase inhibitor
companies
trials
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLA Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsA Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)A Study of Olverembatinib in SDH-deficient GIST.APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsAPG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLLStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLStudy of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLStudy of Olverembatinib (HQP1351) in Patients With CML-CP